The global Aptamers Market is estimated to be valued at US$ 6265.49 Mn in 2023 and is expected to exhibit a CAGR of 18.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Aptamers are short, single-stranded DNA or RNA molecules that are selected through an in vitro selection process called Systematic Evolution of Ligands by Exponential enrichment (SELEX) to bind targeted molecules with high affinity and specificity. Aptamers have advantages over conventional antibodies such as low immunogenicity, longer shelf life, smaller size, and ease of production. Aptamers have applications in diagnostics, therapeutics, and research.

Market key trends:

Nucleic acid aptamers is the fastest growing segment fueling the growth of the global aptamers market. Nucleic acid aptamers have advantages over protein-based aptamers such as lower molecular weight, better stability at different pH and temperature, easier production, and lesser batch-to-batch variation. Nucleic acid aptamers have applications in disease diagnosis, drug delivery, and targeted cancer therapy. Increasing R&D investment by leading players for development of novel nucleic acid aptamers is propelling the growth of this segment. For instance, in October 2022, Vivonics Inc. received funding of US$ 14 Mn to advance development of its lead nucleic acid aptamer candidates for oncology indications.

Segment Analysis

The global aptamers market can be segmented based on type, application, technology, and end-user. Based on type, the diagnostics segment is expected to dominate the market during the forecast period. This is due to the increasing use of aptamers in lateral flow assays, electrochemical biosensors, and flow cytometry for disease diagnosis. The segment is exhibiting high demand for early and accurate disease diagnosis.

Key Takeaways

The Global Aptamers Market Size is expected to witness high growth, exhibiting a CAGR of 18.4% over the forecast period, due to increasing R&D investments in aptamer-based therapeutics and diagnostics.

Regional analysis - North America is expected to be the fastest growing as well as dominating regional market during the forecast period. This is attributed to the growing biotechnology and pharmaceutical industries and rising funding for drug discovery and development research activities in the region.

Key players - Key players operating in the aptamers market are Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, NeoNeuro SAS, Aptus Biotech S.L., AM Biotechnologies, LLC, Base Pair Biotechnologies, Vivonics Inc., CAGE Bio Inc., TAGCyx Biotechnologies Inc., AstraZeneca, GlyTech, Inc., GC Biopharma Corp., Achiko AG, Agilent Technologies, Inc., SomaLogic Operating Co., Inc., Amsbio, and IVERIC bio, Inc. Novartis AG and Aptamer Sciences Inc. are identified as the industry leaders due to their robust product portfolios and global market presence.

Get More Insights Here

https://healthcarelatesteditionnews.blogspot.com/2023/12/nucleic-acid-aptamers-is-fastest.html